Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Rev. cuba. hematol. inmunol. hemoter ; 36(3): e1277, jul.-set. 2020. tab, graf
Article in Spanish | LILACS, CUMED | ID: biblio-1156444

ABSTRACT

Introducción: La aplasia medular adquirida grave es una enfermedad hematológica infrecuente caracterizada por una disminución o ausencia de precursores hematopoyéticos en la médula ósea, lo cual se expresa con distintos grados de citopenias. Varios factores, infecciosos o no, pueden incidir en su origen. Su manejo es complejo y puede incluir tratamiento inmunosupresor y trasplante de progenitores hematopoyéticos alogénico. Objetivo: Demostrar la utilidad de la realización del trasplante de progenitores hematopoyéticos alogénico haploidéntico en pacientes con aplasia medular grave. Caso clínico: Paciente masculino de 21 años de edad, con antecedentes de salud, que en octubre del 2018 debutó con íctero, pancitopenia, lesiones purpúrico hemorrágicas en piel y mucosas, en el curso de una hepatitis aguda seronegativa. La biopsia de médula ósea mostró aplasia medular severa. Se inició tratamiento inmunosupresor con globulina antitimocίtica, ciclosporina A y metilprednisolona. Al cabo de los 6 meses mantenía trombocitopenia severa con necesidades transfusionales y en octubre de 2019 se decide realizar trasplante de progenitores hematopoyéticos alogénico con donante haploidéntico y empleando como tratamiento acondicionante globulina antitimocίtica, fludarabina, ciclofosfamida y bajas dosis de irradiación corporal total. En evaluación clίnica de julio de 2020 (dίa + 280 del trasplante) el paciente estaba asintomático y con parámetros hematológicos normales. Conclusiones: Se demostró que el trasplante de progenitores hematopoyéticos alogénico haploidéntico es un proceder realizable y útil en pacientes con aplasia medular grave, lo cual corrobora el beneficio clínico que puede aportar su ejecución en pacientes con esta enfermedad(AU)


Introduction: Acquired severe marrow aplasia is a rare hematological disease characterized by decrease or absence of hematopoietic precursors in bone marrow, which is expressed with different degrees of cytopenias. Several factors, infectious or not, can influence its origin. Its management is complex and may include immunosuppressive treatment and allogeneic hematopoietic stem-cell transplantation. Objective: To demonstrate the usefulness of performing haploidentical allogeneic hematopoietic stem-cell transplantation in patients with severe medullary aplasia. Clinical case: A 21-year-old male patient, with medical history, who first presented, in October 2018, with icterus, pancytopenia, as well as purpuric hemorrhagic lesions on the skin and mucosa, in the course of acute seronegative hepatitis. The bone marrow biopsy showed severe marrow aplasia. Immunosuppressive treatment was started with antithymocytic globulin, cyclosporine A, and methylprednisolone. After six months, he maintained severe thrombocytopenia under transfusion requirements and, in October 2019, the decision was to perform allogeneic hematopoietic stem-cell transplantation with a haploidentical donor and using antithymocyte globulin, fludarabine, cyclophosphamide, and low doses of total body irradiation as conditioning treatment. In the clinical assessment carried out in July 2020 (day +280 after transplantation), the patient was asymptomatic and with normal hematological parameters. Conclusions: Transplantation of haploidentic allogeneic hematopoietic progenitors was shown to be a feasible and useful procedure in patients with severe marrow aplasia, which corroborates the clinical benefit that its execution can bring in patients with this disease(AU)


Subject(s)
Humans , Male , Young Adult , Tissue Donors/ethics , Methylprednisolone/therapeutic use , Whole-Body Irradiation/methods , Microscopy, Electron, Scanning Transmission/methods , Hematologic Diseases , Hematopoietic Stem Cell Transplantation/methods , Cuba , Transplantation, Haploidentical/methods , Anemia, Aplastic/therapy , Antilymphocyte Serum
2.
Rev. bras. cancerol ; 66(1): 1-12, 20200129.
Article in Portuguese | LILACS | ID: biblio-1095220

ABSTRACT

Introdução: O transplante haploidêntico (haplo) vem crescendo em números e se tornando uma alternativa viável para pacientes sem doadores compatíveis. Uma assistência de enfermagem qualificada também é muito importante para o seu sucesso. Portanto, torna-se necessário adquirir conhecimentos e habilidades no assunto. Objetivo: Descrever as características clínicas e complicações do haplo com ciclofosfamida pós-transplante e discutir suas implicações para a assistência de enfermagem. Método: Revisão integrativa da literatura publicada a partir de 2014, pesquisada nas bases da Biblioteca Virtual em Saúde com o descritor "haploidentical transplantation" e selecionada com critérios pré-definidos. Resultados: Vinte e cinco textos foram revisados; todos da área médica e compostos principalmente de estudos de coorte retrospectivos com amostras pequenas. Entre as características mais prevalentes, destacaram-se: a mãe como principal doadora para crianças (5/7 estudos); regime não mieloablativo (52%); e enxerto de sangue periférico (56%). Além da doença enxerto versus hospedeiro e da rejeição, as complicações mais descritas foram: cistite hemorrágica por vírus BK (56%) e reativação do citomegalovírus (48%); e as com maiores variações nas frequências foram mucosite (8% a 100%) e febre não infecciosa (22% a 100%). As principais causas de mortalidade foram a recaída da doença (3% a 35%) e as infecções (3% a 32%). Conclusão: Esta revisão alertou para a necessidade de aprimoramento da assistência na administração da ciclofosfamida pós-transplante, no suporte aos doadores e no manejo da febre não infecciosa, das infecções virais e da cistite hemorrágica, para que haja melhora na qualidade de vida dos pacientes e diminuição na morbidade e na mortalidade relacionadas ao haplo.


Introduction: Haploidentical Transplantation (haplo) has been growing in numbers and becoming a viable alternative for patients without compatible donors. Qualified nursing care is also very important for its success. Therefore, it becomes necessary to acquire knowledge and skills about the subject. Objective: To describe clinical characteristics and complications of haplo with post-transplant cyclophosphamide and discuss its implications for nursing care. Method: Integrative literature review published from 2014, searched in the bases of the "Biblioteca Virtual em Saúde" with the descriptor "haploidentical transplantation" and selected with predefined criteria. Results:Twenty-five texts were reviewed, all of them of the medical area and consisting mainly of retrospective cohort studies with small samples. Among the most prevalent characteristics, the following were outstanding: the mother as the main donor for children (5/7 studies); non-myeloablative regimen (52%) and peripheral blood graft (56%). In addition to graft versus host disease and rejection, the most described complications were: BK virus hemorrhagic cystitis (56%) and reactivation of cytomegalovirus (48%); and the ones with the highest variations in frequencies were mucositis (8% to 100%) and non-infectious fever (22% to 100%). The main causes of mortality were relapse of the disease (3% to 35%) and infections (3% to 32%). Conclusion: This review warned about the necessity of improving the care in the administration of post-cyclophosphamide, the support to donors and management of non-infectious fever, viral infections and hemorrhagic cystitis to improve the quality of life of patients and reduce haplo-related morbidity and mortality.


Introducción: El diagnóstico precoz del riesgo nutricional puede mejorar el pronóstico de los pacientes onco-hematológicos. Objetivo: Describir el estado nutricional en los pacientes onco-hematológicos y evaluar los factores asociados al riesgo nutricional en los pacientes onco-hematológicos de un Hospital Universitario Terciario de Fortaleza - Ceará. Método: Estudio transversal que incluyó a 127 pacientes adultos internados. Los datos de diagnóstico clínico y demográfico fueron recolectados a través de análisis de prontuarios. El estado nutricional fue evaluado por el índice de masa corporal (IMC), circunferencia braquial (CB) y por la aplicación de la herramienta de clasificación de riesgo nutricional - NRS-2002. Resultados: Diferentes parámetros, hubo divergencias en el estado nutricional. La mayoría de la muestra presentaba riesgo nutricional de acuerdo con la evaluación de la NRS-2002 70,1% (n=89), seguida por la CB 33,9% (n=43) y por IMC 8,7% (n=11). Se observó una correlación positiva significativa entre el IMC y la edad [r=0,313, p<0,001] y CB [r=0,846, p<0,001]. Se observó una asociación significativa NRS-2002≥3, e IMC<18,5 kg/m² (p=0,023) y CB desnutrida (p=0,001). Hubo asociación significativa entre IMC<18,5kg/m² y CB desnutrida (p=0,001), y entre residir en zona urbana y presentar CB adecuado (p=0,023). Conclusión: Alta prevalencia de riesgo nutricional, así como una asociación significativa entre riesgo nutricional y bajos valores de IMC y CB, y residir en zonas rurales. Hay la necesidad de utilizar una combinación de indicadores para diagnosticar de forma más precisa y precoz el estado nutricional de estos pacientes.


Subject(s)
Humans , Male , Female , Cyclophosphamide/administration & dosage , Transplantation, Haploidentical/adverse effects , Transplantation, Haploidentical/nursing , Graft vs Host Disease/complications
3.
Rev. colomb. cancerol ; 23(1): 12-17, ene.-mar. 2019. tab, graf
Article in Spanish | LILACS | ID: biblio-1042744

ABSTRACT

Resumen Introducción: En pacientes con leucemia mieloide aguda (LMA) el trasplante de progenitores hematopoyético (TPH) es el único tratamientoz curativo. El objetivo de este estudio es presentar la experiencia y resultados del trasplante haploidéntico en pacientes adultos con LMA en la Fundación Valle del Lili, Cali - Colombia. Materiales y métodos: Estudio de cohorte retrospectivo de pacientes que recibieron trasplante haploidéntico entre 2013 y 2017, con acondicionamiento mieloablativo y ciclofosfamida postrasplante, en Fundación Valle del Lili, Cali (Colombia). Resultados: Se realizaron 47 trasplantes en pacientes con leucemia mieloide aguda en la fecha de estudio, se incluyeron en el análisis 21 pacientes con donante haploidéntico, a 3 años tanto la supervivencia global y libre de eventos fue del 38%. La incidencia acumulada de mortalidad relacionada al trasplante fue del 26% a 100 días y del 38,3%, a 38 meses de seguimiento. La incidencia acumulada de recaída a 38 meses fue del 19%. Con respecto a la enfermedad injerto versus huésped (EICH) se encontró que la incidencia acumulada de EICH aguda grado II-IV, grado III-IV y EICH crónico fue del 19%, 5% y 19% respectivamente. Conclusión: Los resultados de este estudio sugieren que el trasplante haploidéntico es una alternativa factible como tratamiento para pacientes con diagnóstico de LMA en nuestro medio.


Abstract Introduction: In patients with acute myeloid leukemia (AML), hematopoietic progenitor transplantation (PHT) is the only curative treatment. The objective of this study is to present the experience and results of haploidentical transplantation in adult patients with AML at the Valle del Lili Foundation, Cali - Colombia. Materials and methods: Retrospective cohort study of patients who received haploidentical transplantation between 2013 and 2017, with myeloablative conditioning and post-transplant cyclophosphamide, in Fundación Valle del Lili, Cali (Colombia). Results: 47 transplants were performed in patients with acute myeloid leukemia on the study date, 21 patients with haploidentical donors were included in the analysis, at 3 years both overall and event-free survival was 38%. The cumulative incidence of transplant-related mortality was 26% at 100 days and 38.3% at 38 months of follow-up. The cumulative incidence of relapse at 38 months was 19%. Regarding graft versus host disease (GVHD), it was found that the cumulative incidence of acute GVHD grade II-IV, grade III-IV and chronic GVHD was 19%, 5% and 19% respectively. Conclusion: The results of this study suggest that haploidentical transplantation is a feasible alternative as a treatment for patients diagnosed with AML in our environment.


Subject(s)
Leukemia, Myeloid, Acute , Transplantation, Haploidentical
6.
Chinese Medical Journal ; (24): 2185-2192, 2018.
Article in English | WPRIM | ID: wpr-690246

ABSTRACT

<p><b>Background</b>The dose of certain cell types in allografts affects engraftment kinetics and clinical outcomes after allogeneic stem cell transplantation (SCT). Hence, the present study investigated the association of cell compositions in allografts with outcomes after unmanipulated haploidentical SCT (haplo-SCT) for patients with acquired severe aplastic anemia (SAA).</p><p><b>Methods</b>A total of 131 patients with SAA who underwent haplo-SCT were retrospectively enrolled. Cell subsets in allografts were determined using flow cytometry. To analyze the association of cellular compositions and outcomes, Mann-Whitney U nonparametric tests were conducted for patient age, sex, weight, human leukocyte antigen mismatched loci, ABO-matched status, patient ABO blood type, donor-recipient sex match, donor-recipient relationship, and each graft component. Multivariate analysis was performed using logistic regression to determine independent influence factors involving dichotomous variables selected from the univariate analysis.</p><p><b>Results</b>A total of 126 patients (97.7%) achieved neutrophil engraftment, and 121 patients (95.7%) achieved platelet engraftment. At 100 days after transplantation, the cumulative incidence of II-IV acute graft-versus-host disease (GVHD) was 32.6%. After a median follow-up of 842 (range: 124-4110) days for surviving patients, the cumulative incidence of total chronic GVHD at 3 years after transplantation was 33.7%. The probability of overall survival at 3 years was 83.0%. Multivariate analysis showed that higher total doses of CD14 (P = 0.018) and CD34 cells (P < 0.001) were associated with a successful platelet engraftment. A successful platelet was associated with superior survival (P < 0.001). No correlation of other cell components with outcomes was observed.</p><p><b>Conclusions</b>These results provide evidence and explain that higher doses of CD34 and CD14 cells in haploidentical allografts positively affect platelet engraftment, contributing to superior survival for patients with SAA.</p>


Subject(s)
Adolescent , Adult , Allografts , Anemia, Aplastic , Therapeutics , Child , Child, Preschool , Female , Graft vs Host Disease , Hematopoietic Stem Cell Transplantation , Humans , Male , Middle Aged , Retrospective Studies , Transplantation Conditioning , Transplantation, Haploidentical , Transplantation, Homologous , Young Adult
7.
Rev. cuba. hematol. inmunol. hemoter ; 33(3): 27-36, jul.-set. 2017. tab
Article in Spanish | LILACS | ID: biblio-960418

ABSTRACT

El trasplante de células progenitoras hematopoyéticas es una terapia potencialmente curativa para pacientes con diversas enfermedades; pero solo el 25 - 30 por ciento de estos cuenta con un hermano compatible para el sistema de antígenos leucocitarios humanos. Hace algunos años se ha desarrollado el trasplante con un solo haplotipo idéntico; el que está disponible para la mayoría de los pacientes y se ha llamado trasplante haploidéntico. Se han realizado diferentes intentos para depletar la médula de linfocitos T antes de ser infundida, debido principalmente, a la frecuencia de enfermedad injerto contra huésped en este tipo de trasplante; lo que se asocia con una mayor falla primaria de injerto y a una lenta recuperación inmune. En la actualidad se realizan varios métodos que permiten sortear estos inconvenientes, por lo que este trasplante surge como una alternativa importante para los que no tienen un hermano totalmente compatible y tiene como ventajas que permite escoger entre varios candidatos y evitar la pérdida de tiempo en búsquedas de donantes no familiares(AU)


Hematopoietic stem cell transplantation is a potentially curative therapy for patients with various diseases, but only 25- 30 percent have a compatible donor for human leukocyte antigen. A few years ago it has been developed a transplant with only one identical haplotype; which it is available for most patients, and has been called haploidentical transplantation. There have been attempts to deplete the marrow of T lymphocytes before being infused, mainly due to the presence graft-versus-host disease, and this can lead to primary graft failure and a slow immune recovery. At present, several methods to overcome these drawbacks are made, so this transplantation emerges as an important alternative for those who do not have a fully matched sibling and has the advantage that allows choosing between several candidates and prevents loss of time searching unrelated donor(AU)


Subject(s)
Haplotypes/immunology , Hematopoietic Stem Cell Transplantation/methods , Transplantation, Haploidentical/methods
8.
In. Decaro, Jorge; Lemos, José Felipe. Medicina transfusional en el trasplante de células progenitoras hematopoyéticas. Montevideo, s.n, 2017. p.291-320, tab.
Monography in Spanish | LILACS, BNUY, UY-BNMED | ID: biblio-1290488
9.
ARS med. (Santiago, En línea) ; 41(2): 50-53, 2016. Tab
Article in Spanish | LILACS | ID: biblio-1016204

ABSTRACT

El trasplante hematopoyético es una estrategia terapéutica que permite posibilidad de curación en diversas enfermedades benignas y malignas. El autotrasplante tiene demostrada utilidad en mieloma y linfomas permitiendo recuperar la hematopoyesis luego de quimioterapias de alta intensidad. El alotrasplante permite reemplazar hematopoyesis defectuosa y/o introducir un potente efecto inmunológico llamado "efecto de injerto contra tumor". En los últimos años, se han desarrollado nuevos fármacos que permiten optimizar la recolección de progenitores autólogos y se han modificado los esquemas de trasplante, permitiendo un uso más amplio. El haplo trasplante alogénico ha favorecido que los enfermos tengan mejores posibilidades de encontrar donantes. En esta revisión, se analizan brevemente estas nuevas modalidades adoptadas en nuestro programa de trasplante hematopoyético.(AU)


Hematopoietic transplantation offers cure or control in several benign or malignant diseases. Autologous transplantation has proven to be useful in myeloma and lymphoma patients allowing hematopoiesis recovery after high-intensity chemotherapies. Allogeneic transplantation can replace defective hematopoiesis and / or introduce graft-versus-tumor effect. In recent years, new strategies have been developed to optimize autologous progenitor's collection and haploidentical modalities have allowed a wider use of allotransplants. In this brief review these new modalities adopted in our program are analyzed.(AU)


Subject(s)
Humans , Male , Female , Transplantation , Transplantation, Autologous , Transplantation, Haploidentical , Hematopoietic System
SELECTION OF CITATIONS
SEARCH DETAIL